Compare Entegris Inc (ENTG) vs Hims and Hers Health Inc (HIMS) Price & Performance

ENTG trades at $162.19, down 2.48% today but maintains strong technical momentum with bullish moving averages and key support at $158. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.93 exceeding expectations by 13%. Revenue remains stable at $3.2B annually while net margins improved to 9.18% in 2026. Recent institutional buying from BlackRock and Baird Financial Group signals confidence in the semiconductor materials supplier.

ENTG presents a compelling growth story driven by AI semiconductor demand and operational improvements, with analyst consensus targeting 12.5% upside to $182.43. However, elevated valuation multiples (P/E 81.1, EV/EBITDA 31.7) and high long-term debt of $3.98B create vulnerability to sector downturns. The stock's performance hinges on continued execution amid semiconductor cycle volatility.

HIMS stock trades at $28.06, down 5.01% on the day, reflecting bearish technical signals and negative earnings surprises in recent quarters. The company reported strong revenue growth to $2.35 billion in 2025 but swung to a net loss of -$142 million in 2026, with profitability metrics deteriorating. Multiple securities class action lawsuits filed in October 2026 create significant legal overhangs, while analyst consensus remains cautiously optimistic with a $32.17 price target despite mixed fundamental performance.

The outlook is clouded by legal risks and profitability challenges, though the 15% upside to consensus target suggests potential recovery if execution improves. Key risks include ongoing litigation outcomes and the company's ability to return to sustainable profitability amid competitive pressures in the telehealth sector.